Ergo Science Ergoset
Executive Summary
Ortho-McNeil will market bromocriptine mesylate and other products developed by the companies for Type 2 diabetes and obesity in the U.S. and J&J companies will market products worldwide under an agreement announced Feb. 24. Ergo will receive $40 mil. in payments and equity and share equally in costs and profits. The NDA for dopamine-receptor agonist Ergoset was filed in October...